Does Rallies show Form 4 insider transactions for BIOA?

Yes. Rallies tracks BIOA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BIOA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BIOA. It does not provide personalized investment advice.

BIOA (BioAge Labs, Inc. Common Stock) Stock Analysis - Insider Trades

BioAge Labs, Inc. Common Stock (BIOA) is a publicly traded Healthcare sector company. As of May 20, 2026, BIOA trades at $16.26 with a market cap of $681.90M and a P/E ratio of -6.84. BIOA moved -0.61% today. Year to date, BIOA is +27.59%; over the trailing twelve months it is +315.48%. Its 52-week range spans $2.88 to $26.62. Analyst consensus is buy with an average price target of $47.83. Rallies surfaces BIOA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BIOA stock inside the company?

Recent BIOA insider activity includes RUBIN PAUL D sold 8.82K, RUBIN PAUL D sold 7.43K, RUBIN PAUL D sold 7.43K, GOLDSTEIN DOV A MD sold 8.97K, and GOLDSTEIN DOV A MD sold 4.44K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BIOA Key Metrics

Key financial metrics for BIOA
Metric	Value
Price	$16.26
Market Cap	$681.90M
P/E Ratio	-6.84
EPS	$-2.40
Dividend Yield	0.00%
52-Week High	$26.62
52-Week Low	$2.88
Volume	147.40K
Avg Volume	0
Revenue (TTM)	$10.32M
Net Income	$-89.93M
Gross Margin	0.00%

Recent BIOA Insider Trades

RUBIN PAUL D sold 8.82K (~$157.08K) on Apr 1, 2026.
RUBIN PAUL D sold 7.43K (~$150.89K) on Mar 2, 2026.
RUBIN PAUL D sold 7.43K (~$139.37K) on Feb 2, 2026.
GOLDSTEIN DOV A MD sold 8.97K (~$165.37K) on Jan 13, 2026.
GOLDSTEIN DOV A MD sold 4.44K (~$86.37K) on Jan 13, 2026.

Latest BIOA News

Cell Therapy Market to Top $20 Billion by 2030 as BioAge Labs Advances Anti-Aging Research — May 20, 2026
BioAge Achieves 86% hsCRP Reduction in Phase 1, Secures $132.3M — May 8, 2026
BioAge to Unveil BGE-102 Phase 1 NLRP3 Inhibitor Data on May 8 — May 4, 2026
BioAge’s BGE-102 Delivers 85–87% hsCRP Cuts, Launching Mid-2026 Phase 2 Trial — Apr 21, 2026
BioAge Labs Raises $132.3M and Reports 86% BGE-102 Phase 1 hsCRP Reduction — Mar 24, 2026

BIOA Analyst Consensus

7 analysts cover BIOA: 0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.83.

Common questions about BIOA

Who is trading BIOA stock inside the company?: Recent BIOA insider activity includes RUBIN PAUL D sold 8.82K, RUBIN PAUL D sold 7.43K, RUBIN PAUL D sold 7.43K, GOLDSTEIN DOV A MD sold 8.97K, and GOLDSTEIN DOV A MD sold 4.44K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BIOA?: Yes. Rallies tracks BIOA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BIOA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BIOA. It does not provide personalized investment advice.